High levels of a form of the CD146 protein, normally found on endothelial cells — those that line blood vessel walls — may be a potential biomarker in identifying people with systemic sclerosis (SSc), a study suggests. Certain forms of the protein are implicated in lung scarring (pulmonary fibrosis)…
News
People with systemic sclerosis (SSc) vaccinated for COVID-19 fare well, with no serious adverse events and a low rate of reported flares, according to an international survey. “To our knowledge, this is the first large study that details experiences with COVID-19 vaccines in systemic sclerosis. Vaccination was safe in this group,”…
Acazicolcept (ALPN-101), an experimental therapy that blocks T-cell activation and is being developed by Alpine Immune Sciences, was found effective at decreasing scarring in mouse models of systemic sclerosis (SSc). A team of scientists at Alpine and other institutions published their findings in a study, “…
The U.S. Food and Drug Administration (FDA) has approved a clinical trial to determine the safety and efficacy of adipose-derived regenerative cells (ADRCs) for the treatment of hand dysfunction in patients with diffuse cutaneous scleroderma, Paracrine has announced. The Phase 3 trial, called STAR…
Slowing the decline in lung function, even small reductions, may prevent hospitalizations in patients with interstitial lung disease associated with systemic sclerosis (SSc-ILD), according to a post-hoc analysis of the Phase 3 SENSCIS trial. Researchers found that a greater decline in lung function is significantly associated with an…
When gene expression — the process in which a gene gets turned ‘on’ in a cell to make proteins — is dysregulated or does not function the way it should normally, the affected skin of patients with systemic sclerosis (SSc) tends to be abnormally thicker, a study has found.
The Scleroderma Research Foundation (SRF) will match every dollar donated in honor of the late comedian Bob Saget — a 30-year board member — up to $1.5 million. The matching gift was donated by fellow board members Luke Evnin, PhD, and Deann Wright after family, friends, and fans sought…
The Scleroderma Foundation is relaunching itself under a new name, the National Scleroderma Foundation, intending to reach and educate a larger audience and connect more of those affected by scleroderma with the resources they need. “The scope of our work is nationwide,” Mary Wheatley, CEO of the National…
People with systemic sclerosis (SSc) in Brazil had a weaker immune response to the CoronaVac COVID-19 vaccine than did healthy individuals, a study discovered. The findings also showed that treatment with the immunosuppressant therapy CellCept (mycophenolate mofetil) — an oral medication that improves lung function in SSc patients…
Several risk factors for diastolic dysfunction (DD), the heart’s inability to fill with blood properly after it beats, were identified in people with systemic sclerosis (SSc) in a recent study. These risk factors, such as obesity, could be potentially modified to reduce the occurrence of more serious disease outcomes,…
Recent Posts
- Nearly half with SSc consider facial cosmetic therapy, survey finds
- Inhaled therapy for Raynaud’s attacks put on FDA fast track
- Vitamin B3 may improve blood vessels in scleroderma-related Raynaud’s
- John Stamos to be honored for longtime support of scleroderma research
- Study maps shift in prescribing patterns as guidelines evolve
- Blood protein may help predict lung decline in scleroderma-related ILD
- Lack of small blood vessel damage patterns may predict milder SSc
- Wireless sensor may help track scleroderma skin changes at home
- New scleroderma survey seeks patient input to guide future research
- Scleroderma added to NIH project targeting autoimmune diseases